Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

107 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Do patients participating in clinical trials want to know study results?
Partridge AH, Burstein HJ, Gelman RS, Marcom PK, Winer EP. Partridge AH, et al. Among authors: marcom pk. J Natl Cancer Inst. 2003 Mar 19;95(6):491-2. doi: 10.1093/jnci/95.6.491. J Natl Cancer Inst. 2003. PMID: 12644548 No abstract available.
NCCN Guidelines Insights Breast Cancer, Version 1.2016.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Gradishar WJ, et al. Among authors: marcom pk. J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85. doi: 10.6004/jnccn.2015.0176. J Natl Compr Canc Netw. 2015. PMID: 26656517
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
Saha A, Harowicz MR, Cain EH, Hall AH, Hwang ES, Marks JR, Marcom PK, Mazurowski MA. Saha A, et al. Among authors: marcom pk. Breast Cancer Res Treat. 2018 Nov;172(1):123-132. doi: 10.1007/s10549-018-4879-7. Epub 2018 Jul 10. Breast Cancer Res Treat. 2018. PMID: 29992418 Free PMC article.
Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.
Peppercorn J, Hamilton E, Marcom PK, Beskow L, Lyman GH. Peppercorn J, et al. Among authors: marcom pk. Cancer. 2013 Oct 15;119(20):3703-9. doi: 10.1002/cncr.28263. Epub 2013 Jul 24. Cancer. 2013. PMID: 23893861 Clinical Trial.
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, Anders C, Devi GR, Lyerly HK, Clay TM. Morse MA, et al. Among authors: marcom pk. J Transl Med. 2007 Sep 6;5:42. doi: 10.1186/1479-5876-5-42. J Transl Med. 2007. PMID: 17822557 Free PMC article. Clinical Trial.
Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.
Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK, Pizzo SV, Bachelder RE. Li S, et al. Among authors: marcom pk. Breast Cancer Res. 2015 Jul 4;17(1):91. doi: 10.1186/s13058-015-0590-3. Breast Cancer Res. 2015. PMID: 26141457 Free PMC article.
Nuclear bFGF-mediated chemo-resistance is associated with increased DNA-dependent protein kinase (DNA-PK) expression and accelerated DNA repair. ...
Nuclear bFGF-mediated chemo-resistance is associated with increased DNA-dependent protein kinase (DNA-PK) expression and accelerated …
The impact of sharing results of a randomized breast cancer clinical trial with study participants.
Partridge AH, Wolff AC, Marcom PK, Kaufman PA, Zhang L, Gelman R, Moore C, Lake D, Fleming GF, Rugo HS, Atkins J, Sampson E, Collyar D, Winer EP. Partridge AH, et al. Among authors: marcom pk. Breast Cancer Res Treat. 2009 May;115(1):123-9. doi: 10.1007/s10549-008-0057-7. Epub 2008 Jun 10. Breast Cancer Res Treat. 2009. PMID: 18543100 Clinical Trial.
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Han HS, et al. Among authors: marcom pk. Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505. Ann Oncol. 2018. PMID: 29045554 Free PMC article. Clinical Trial.
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM. Barroso-Sousa R, et al. Among authors: marcom pk. Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047. Ann Oncol. 2019. PMID: 30753274 Clinical Trial.
Phase I study of Doxil and vinorelbine in metastatic breast cancer.
Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, Matulonis UA, Parker LM, Harris LN, Winer EP. Burstein HJ, et al. Among authors: marcom pk. Ann Oncol. 1999 Sep;10(9):1113-6. doi: 10.1023/a:1008323200102. Ann Oncol. 1999. PMID: 10572612 Clinical Trial.
107 results
Jump to page
Feedback